...
首页> 外文期刊>Frontiers in Microbiology >Comparison of Two Molecular Assays for Detection and Characterization of Aspergillus fumigatus Triazole Resistance and Cyp51A Mutations in Clinical Isolates and Primary Clinical Samples of Immunocompromised Patients
【24h】

Comparison of Two Molecular Assays for Detection and Characterization of Aspergillus fumigatus Triazole Resistance and Cyp51A Mutations in Clinical Isolates and Primary Clinical Samples of Immunocompromised Patients

机译:免疫受损患者临床分离株和原发性临床样品中两种检测和表征烟曲霉,三唑耐药和突变的Cyp51A突变的分子检测方法的比较

获取原文
           

摘要

In hematological patients, the incidence of invasive aspergillosis (IA) caused by azole resistant Aspergillus fumigatus (ARAf) is rising. As the diagnosis of IA is rarely based on positive culture in this group of patients, molecular detection of resistance mutations directly from clinical samples is crucial. In addition to the in-house azole resistance ARAf polymerase chain reaction (PCR) assays detecting the frequent mutation combinations TR34/L98H, TR46/Y121F/T289A, and M220 in the Aspergillus fumigatus ( A. fumigatus ) Cyp51A gene by subsequent DNA sequence analysis, we investigated in parallel the commercially available AsperGenius? real time PCR system in detecting the Cyp51A alterations TR34/L98H and Y121F/T289A directly from 52 clinical samples (15 biopsies, 22 bronchoalveolar lavage (BAL), 15 cerebrospinal fluid (CSF) samples) and ARAf isolates ( n = 3) of immunocompromised patients. We analyzed DNA aliquots and compared both methods concerning amplification and detection of Aspergillus DNA and Cyp51A alterations. As positive control for the feasibility of our novel Y121F and T289A PCR assays, we used two A. fumigatus isolates with the TR46/Y121F/T289A mutation combination isolated from hematological patients with known C yp51A alterations and a lung biopsy sample of a patient with acute myeloid leukemia (AML). The rate of positive ARAf PCR results plus successful sequencing using the ARAf PCR assays was 61% in biopsies, 29% in CSF, 67% in BAL samples and 100% in isolates. In comparison the amount of positive PCRs using the AsperGenius? assays was 47% in biopsies, 42% in CSF, 59% in BAL samples and 100% in isolates. Altogether 17 Cyp51A alterations were detected using our ARAf PCRs plus DNA sequencing and therefrom 10 alterations also by the AsperGenius? system. The comparative evaluation of our data revealed that our conventional PCR assays are more sensitive in detecting ARAf in BAL and biopsy samples, whereby differences were not significant. The advantage of the AsperGenius? system is the time saving aspect. We consider non-culture based molecular detection of Aspergillus triazole resistance to be of high epidemiological and clinical relevance in patients with hematological malignancies.
机译:在血液病患者中,由对唑类耐药的烟曲霉(ARAf)引起的侵袭性曲霉病(IA)的发病率正在上升。由于在这一组患者中IA的诊断很少基于阳性培养,因此直接从临床样品中检测耐药性突变的分子检测至关重要。除了内部的唑抗性ARAf聚合酶链反应(PCR)分析法,还通过后续DNA序列分析检测了烟曲霉(A. fumigatus)Cyp51A基因中的频繁突变组合TR34 / L98H,TR46 / Y121F / T289A和M220 ,我们平行研究了市售的AsperGenius?实时PCR系统可直接从52个临床样本(15个活检,22个支气管肺泡灌洗(BAL),15个脑脊髓液(CSF)样本)和ARAf分离株(n = 3)中检测Cyp51A突变TR34 / L98H和Y121F / T289A耐心。我们分析了DNA等分试样,并比较了有关扩增和检测曲霉DNA和Cyp51A改变的两种方法。作为我们新型Y121F和T289A PCR检测方法可行性的阳性对照,我们使用了两种烟曲霉菌株,分别从已知C yp51A改变的血液病患者中分离出TR46 / Y121F / T289A突变组合,并从急性患者的肺活检样本中骨髓性白血病(AML)。 ARAf PCR阳性结果加上使用ARAf PCR分析成功测序的比率在活检中为61%,在CSF中为29%,在BAL样品中为67%,在分离物中为100%。相比之下,使用AsperGenius进行阳性PCR的数量?活检中47%,CSF中42%,BAL样品中59%,分离物中100%。使用我们的ARAf PCR和DNA测序技术,一共检测到17种Cyp51A改变,而AsperGenius®还从中检测出10种改变。系统。对我们数据的比较评估表明,我们常规的PCR检测方法在检测BAL和活检样本中的ARAf时更为敏感,因此差异不显着。 AsperGenius的优势?系统是节省时间的方面。我们认为对血液系统恶性肿瘤患者,基于非培养物的三唑曲霉抗药性分子检测具有很高的流行病学和临床意义。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号